Key Takeaways Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled.However, the health and ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...

While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of ...

Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new ...

Hims is doubling down on ambitionand it just brought in a heavy hitter to do it. Nader Kabbani, the architect behind Amazon ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers Health appoints former Amazon executive Nader Kabbani as its chief operating officer. The telehealth-consultation platform on Monday said Kabbani will oversee operations as the company ...

In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other Friday’s top performers. The stock market ended the trading week on a strong note ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put ...